HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,712 | +10.3% | 44,820 | +4.2% | 0.01% | 0.0% |
| Q2 2023 | $1,552 | +38.3% | 43,030 | +46.5% | 0.01% | +25.0% |
| Q1 2023 | $1,122 | -61.2% | 29,375 | -42.2% | 0.00% | -63.6% |
| Q4 2022 | $2,890 | -99.8% | 50,789 | +19.1% | 0.01% | +57.1% |
| Q3 2022 | $1,687,000 | +1.3% | 42,658 | +12.7% | 0.01% | 0.0% |
| Q2 2022 | $1,665,000 | +38.2% | 37,840 | +25.2% | 0.01% | +40.0% |
| Q1 2022 | $1,205,000 | +14.0% | 30,219 | +14.9% | 0.01% | +25.0% |
| Q4 2021 | $1,057,000 | -13.1% | 26,291 | -12.1% | 0.00% | -20.0% |
| Q3 2021 | $1,217,000 | -20.5% | 29,920 | -11.2% | 0.01% | -28.6% |
| Q2 2021 | $1,530,000 | +15.8% | 33,693 | +6.3% | 0.01% | 0.0% |
| Q1 2021 | $1,321,000 | +32.2% | 31,704 | +35.5% | 0.01% | +16.7% |
| Q4 2020 | $999,000 | -27.3% | 23,392 | -55.3% | 0.01% | -33.3% |
| Q3 2020 | $1,375,000 | -1.7% | 52,317 | +0.2% | 0.01% | 0.0% |
| Q2 2020 | $1,399,000 | – | 52,187 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 7,048,282 | $126,799,000 | 27.23% |
| First Light Asset Management, LLC | 1,630,591 | $29,334,000 | 5.01% |
| SNYDER CAPITAL MANAGEMENT L P | 3,393,057 | $61,041,000 | 3.48% |
| Bellevue Group AG | 7,663,956 | $137,874,000 | 2.67% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 307,633 | $5,531,000 | 2.52% |
| Lombard Odier Asset Management (Switzerland) SA | 900,000 | $16,191,000 | 2.17% |
| Elk Creek Partners, LLC | 654,362 | $11,772,000 | 2.02% |
| DOHENY ASSET MANAGEMENT /CA | 127,110 | $2,254,000 | 1.79% |
| Granite Investment Partners, LLC | 1,277,438 | $22,981,000 | 1.49% |
| Amia Capital LLP | 69,409 | $1,249,000 | 1.11% |